<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies</h2>
    <div class="badge">2025-09-08T10:30:00+00:00</div>
    <ul>
      <li>May 2024.</li>
<li>08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.</li>
<li>Additional Phase 3 development is planned to begin in the first half of 2026.</li>
<li>About 35% of patients continue to experience moderate to severe symptoms despite standard of care therapy.</li>
<li>Itch was reduced by 52% (p&lt;0.0001), conjunctival redness by 39% (p&lt;0.0001) and skin prick reactivity by 44% (p&lt;0.0001).</li>
<li>Itch was reduced by 51% (p&lt;0.0001), conjunctival redness by 46% (p&lt;0.0001), and skin prick reactivity by 44% (p&lt;0.0001).</li>
<li>In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Regeneron%20Advances%20Allergy%20Pipeline%20with%20Two%20Positive%20Phase%203%20Trials%20Evaluating%20First-in-Class%20Antibody-Blockers%20of%20Cat%20and%20Birch%20Allergies%0A%E2%80%A2%20May%202024.%0A%E2%80%A2%2008%2C%202025%20%28GLOBE%20NEWSWIRE%29%20--%20Regeneron%20Pharmaceuticals%2C%20Inc.%0A%E2%80%A2%20Additional%20Phase%203%20development%20is%20planned%20to%20begin%20in%20the%20first%20half%20of%202026.%0A%E2%80%A2%20About%2035%25%20of%20patients%20continue%20to%20experience%20moderate%20to%20severe%20symptoms%20despite%20standard%20of%20care%20therapy.%0A%E2%80%A2%20Itch%20was%20reduced%20by%2052%25%20%28p%3C0.0001%29%2C%20conjunctival%20redness%20by%2039%25%20%28p%3C0.0001%29%20and%20skin%20prick%20reactivity%20by%2044%25%20%28p%3C0.0001%29.%0A%E2%80%A2%20Itch%20was%20reduced%20by%2051%25%20%28p%3C0.0001%29%2C%20conjunctival%20redness%20by%2046%25%20%28p%3C0.0001%29%2C%20and%20skin%20prick%20reactivity%20by%2044%25%20%28p%3C0.0001%29.%0A%E2%80%A2%20In%20addition%2C%20REGEN-COV%C2%AE%20%28casirivimab%20and%20imdevimab%29%20had%20been%20authorized%20by%20the%20FDA%20during%20the%20COVID-19%20pandemic%20until%202024.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fregeneron-advances-allergy-pipeline-with-two-positive-phase-3-trials-evaluating%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/regeneron-advances-allergy-pipeline-two-103000615.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>